Drug Target Review

JULY 4, 2023

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. Patients and caregivers also assess the benefits offered by different therapies, weighing the progression-free survival with their off-target effects.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. In some cases, cell therapy can be curative for the patient.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Target Review

SEPTEMBER 25, 2024

Most targeted cancer therapies used today operate by inhibiting targets along well-known oncogenic signalling cascades. The reactivation of oncogenic signalling upstream or downstream of the driving oncogene is a well-studied source of resistance to targeted cancer therapies.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. Small molecule GLP1s?

Small Molecule 143

Small Molecule Trials Therapies Disease 143

The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. We look forward to working on this new collaboration with Biohaven, a world leader in the clinical development of CGRP-targeted therapies.” TOKYO and CAMBRIDGE, England , Dec. About Sosei Heptares.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

The Pharma Data

APRIL 6, 2021

Bayer will present new research across its oncology portfolio at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 , taking place over two weeks on April 10-15 and May 17-21, 2021. The compound has also received a breakthrough therapy designation in the U.S.

Research 52

Research Small Molecule Treatment Clinical Trials 52

The Pharma Data

JANUARY 19, 2021

With this kind of a start, 2021 may be scorching. TCR 2 is developing novel T-cell therapies for solid tumors and hematological cancers. The company is using its pioneering FasTCAR and TruUCAR technology platforms to discover and develop breakthrough cell therapies. TCR2 Therapeutics – The Cambridge, Mass.

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

The Pharma Data

JANUARY 31, 2021

1, 2021 12:16 UTC. Patent US10835501B2 Begins Development of Indication BioSciences’ Intellectual Patent Portfolio for statin plus cannabinoid combination therapies. Current statin therapies are associated with adverse effects including myalgia. Issuance of U.S. SILVERTHORNE, Colo.–(

Small Molecule 52

Small Molecule Therapies Clinical Research Pharmaceuticals 52

The Pharma Data

JUNE 22, 2023

Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan SANTA MONICA, Calif.–(BUSINESS –(BUSINESS WIRE)– Kite Pharma, Inc., to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc. Kite’s manufacturing facility in El Segundo, California, U.S.

Therapies 40

Therapies Marketing Small Molecule Science 40

The Pharma Data

AUGUST 7, 2021

Vividion’s platform is able to produce a variety of small molecule therapies across indications, with initial focus on targets relevant to oncology and immunology. The acquisition of Vividion strengthens Bayer’s small molecule capabilities and expands Bayer’s reach into new modalities.

Small Molecule 52

Small Molecule Drugs Therapies Pharmaceutical Companies 52

The Pharma Data

OCTOBER 15, 2020

Vertex Pharmaceuticals has decided to give up on its experimental VX-814, a small molecule drug for the rare genetic disease Alpha-1 antitrypsin deficiency (AATD), canning the drug’s development after seeing lackluster results from an early phase 2 trial. James Miessler.

Disease 52

Disease Small Molecule Pharmacokinetics Licensing 52

Drug Target Review

JUNE 12, 2023

TEAD proteins are known to be very important in cancer progression TEAD proteins are known to be very important in cancer progression, and there are a number of therapies in development. 2021 – and a robust pipeline that includes 3 AI-designed drugs (for IPF, COVID-19 and cancer) currently in clinical trials.

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Pharmacokinetics 92

The Pharma Data

JANUARY 25, 2021

26, 2021 13:00 UTC. –( BUSINESS WIRE )– Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced that the U.S. FREDERICK, Md.–( About VLX-1005.

FDA 52

FDA Small Molecule FDA Approval Drugs 52

The Pharma Data

MARCH 25, 2021

The study evaluated the safety and efficacy of two doses of abrocitinib, 100mg and 200mg, versus placebo in adults with moderate to severe atopic dermatitis who were on background topical therapy. The manuscript was published in the March 25, 2021 issue of NEJM. Both doses of abrocitinib met the co-primary study endpoints.

Small Molecule 52

Small Molecule Therapies Treatment Disease 52

The Pharma Data

NOVEMBER 15, 2020

In a deal set to be finalized early in 2021, Urovant Sciences has agreed to be fully acquired by largest investor and close partner, Sumitovant Biopharma. The company hopes to follow vibegron to the market with URO-902, a novel gene therapy for patients whose OAB has eluded oral pharmacologic therapy.

Science 52

Science Small Molecule FDA Approval Therapies 52

The Pharma Data

SEPTEMBER 8, 2021

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy. Sanofi has entered into a definitive merger agreement with Kadmon Holdings, Inc. Transaction Terms.

FDA Approval 52

FDA Approval Therapies Small Molecule FDA 52

Drug Target Review

MAY 23, 2023

Therapies developed in recent decades have transformed the treatment of IBD, making hospitalisation and surgery less common. However, many patients respond poorly to corticosteroid treatment, or their immune system responds unfavourably to biological therapies, such as the development of autoimmune diseases.

Drugs 75

Drugs Small Molecule Production Disease 75

The Pharma Data

JULY 18, 2021

Pfizer and BioNTech completed the rolling submission of the BLA in May 2021. On May 10, 2021, the FDA expanded the Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to include individuals 12 through 15 years of age. About Pfizer: Breakthroughs That Change Patients’ Lives.

Licensing 52

Licensing Licensing Vaccine FDA 52

The Pharma Data

JANUARY 31, 2021

1, 2021 /PRNewswire/ — AIkido Pharma Inc. Convergent has exclusive rights to technology related to next generation radiopharmaceutical therapy for prostate cancer that is covered by multiple issued U.S. The key component of Convergent’s PRRT prostate cancer therapy is its proprietary drug, CONV 01-?,

Small Molecule 40

Small Molecule FDA Approval Trials Therapies 40

The Pharma Data

JANUARY 5, 2021

06, 2021 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 4:30 p.m. Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process with the goal of bringing life-changing therapies to patients.

Small Molecule 40

Small Molecule Therapies Drugs 40

The Pharma Data

JANUARY 13, 2021

14, 2021 11:00 UTC. Knopp’s clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small-molecule treatments for developmental and epileptic encephalopathies, other epilepsies, neuropathic pain, and tinnitus.

Trials 52

Trials Small Molecule Clinical Trials Treatment 52

NIH Director's Blog: Drug Development

OCTOBER 11, 2022

For clinical researchers, click chemistry has emerged as a workhorse in drug discovery and the improved targeting of cancer chemotherapies and other small-molecule drugs. The approach also is being used to improve delivery of antibody-based therapies and to create new biomaterials. Kolb, HC, Finn, MG, Sharpless, KB.

Research 52

Research Small Molecule Science Clinical Research 52

The Pharma Data

JANUARY 14, 2021

14, 2021 /PRNewswire/ — Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR ® artificial intelligence (“A.I.”) The offering is expected to close on January 20, 2021 , subject to satisfaction of customary closing conditions. DALLAS , Jan.

Small Molecule 52

Small Molecule Therapies Drug Development Drugs 52

The Pharma Data

JANUARY 10, 2021

11, 2021 /PRNewswire/ — On January 8, 2021 , Shenzhen Chipscreen Biosciences Co., Chiauranib as a single agent therapy inhibits the overactive Aurora B pathway existed in and related to molecular mechanism of SCLC, which is an important feature of Chiauranib distinct to other antiangiogenic drugs. SHENZHEN, China , Jan.

Clinical Trials 52

Clinical Trials Treatment Trials Drugs 52

The Pharma Data

JANUARY 19, 2021

20, 2021 (GLOBE NEWSWIRE) — Neuronascent Inc. , This small molecule therapy is presently in Phase 1 clinical trial for mild to moderate Alzheimer’s disease (AD), which is supported by a NIA R01 grant in healthy aged volunteers. CLARKSVILLE, Md., There is a great need for a disease-modifying treatment for the 5.3

Disease 40

Disease Small Molecule Clinical Trials Therapies 40

The Pharma Data

MAY 15, 2023

Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. The company was founded in 2021 by Stephen Kaldor, Ph.D., Qing Dong, Ph.D., and Gene Hung, M.D.,

Small Molecule 40

Small Molecule DNA Immune Response Science 40

The Pharma Data

JANUARY 24, 2021

25, 2021 12:00 UTC. Researchers at Faze are harnessing the power of biomolecular condensates, membrane-less clusters of molecules that dynamically organize to perform a wide array of cell functions, to advance potential breakthrough therapies. CAMBRIDGE, Mass.–( as its chief executive officer (CEO). He earned his B.Sc.

Pharma Companies 52

Pharma Companies Small Molecule Science Disease 52

The Pharma Data

JANUARY 8, 2021

When Chinook Therapeutics looks at 2021, it foresees a host of clinical trials that will bring precision medicine to the kidney disease space. Its application has the potential to enable smaller and faster trials, and thus deliver innovative therapies to a broad population years faster than otherwise would be possible.

Clinical Trials 52

Clinical Trials Small Molecule Trials Disease 52

The Pharma Data

JANUARY 3, 2021

Sixty-two percent of patients were treated with prior PD(L)-1 containing therapy, and the arms were well balanced. million, with the majority to be completed by the first quarter of 2021. More financial details will be provided by the company in its fourth quarter 2020 financial report in March 2021. SOUTH SAN FRANCISCO, Calif.,

Trials 52

Trials Clinical Trials Small Molecule Therapies 52

The Pharma Data

JANUARY 10, 2021

11, 2021 /PRNewswire/ — IDEAYA Biosciences, Inc. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial to evaluate IDE397, a small molecule methionine adenosyltransferase 2a (MAT2A) inhibitor, for the treatment of patients having solid tumors with methylthioadenosine phosphorylase (MTAP) deletion.

FDA 52

FDA Clinical Trials Small Molecule Therapies 52

KIF1A

MAY 27, 2023

KIF1A.ORG provided pilot funding to Dr. Kaur in 2021, which she has leveraged into a 3-year federal grant; she now oversees 5 KAND research projects that utilize our patient-derived cell lines to screen for small molecule therapeutics and test potential gene therapies.

Science 94

Science Small Molecule Disease Research 94

The Pharma Data

JANUARY 4, 2021

5, 2021 06:30 UTC. The Company also expects to start a natural history clinical study in CIO in adult cancer patients in H1 2021. Further details on the trial design will be communicated in H2 2021. Topline data are now anticipated in Q4 2021 rather than mid-2021 as had been previously estimated. About Sensorion.

Clinical Trials 40

Clinical Trials Small Molecule Therapies Treatment 40

The Pharma Data

APRIL 15, 2022

In December 2021, Pfizer and BioNTech announced the companies would test a third 3 µg dose given at least two months after the second dose in children under age 5 and a third dose of the 10 µg formulation in children 5 to under 12 years of age. The trial enrolled children with or without prior evidence of SARS-CoV-2 infection.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

JANUARY 10, 2021

10, 2021 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create product candidates that address unmet medical needs, will provide an update on Vision 3×3 and the company’s 2021 key milestones at the 39 th Annual J.P. ?.

Clinical Trials 40

Clinical Trials Clinical Development Small Molecule Trials 40

The Pharma Data

DECEMBER 15, 2020

a Phase 3 clinical-stage biotech company developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, today announced the appointment of Djordje Filipovic, PhD, as Chief Commercial Officer (CCO). . Joins AB2 Bio from Novartis and has extensive commercial and strategic experience.

Small Molecule 40

Small Molecule Disease Therapies Treatment 40

The Pharma Data

DECEMBER 27, 2020

NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided a year-end review and an outline of its plans for 2021. .–( BUSINESS WIRE )– Lineage Cell Therapeutics, Inc.

Therapies 40

Therapies Clinical Trials Production Treatment 40

KIF1A

JUNE 30, 2023

This program helped obtain wheelchairs for 2 KAND patients and a vibration therapy plate to help one patient with their circulation. Treatment Accelerator Program at NeuCyte In August of 2021, KIF1A.ORG announced its partnership with NeuCyte to launch our very own Treatment Accelerator Program (TAP) for KAND therapeutic discovery.

Small Molecule 52

Small Molecule Treatment Doctors Research 52